Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | SNCA | P37840 | 1/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29352045 | 1.00 | APP (0.79) | APPMAPTSNCAL3MBTL1TNIK | |
| SCHEMBL19575131 | 0.89 | APP (0.79) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL29528164 | 0.88 | APP (1.00) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL21953813 | 0.88 | APP (0.77) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL1727264 | 0.88 | APP (1.00) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL12453200 | 0.88 | APP (1.00) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL17254447 | 0.88 | APP (0.69) | APPMAPTSNCA | |
| SCHEMBL21298993 | 0.86 | APP (0.74) | APPMAPTSNCAKDM2BGABRA1 | |
| SCHEMBL13808727 | 0.86 | APP (0.86) | APPMAPTSNCAKDM2B | |
| SCHEMBL21697833 | 0.85 | APP (0.76) | APPMAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699157-B1 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | UNIV CALIFORNIA (US) | 2018-03-14 | — | — | EP | claimed |
| US-20140140932-A1 | Functionalized Magnetic Nanoparticles and Use in Imaging Amyloid Deposits and Neurofibrillary Tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-22 | — | — | US | claimed |
| EP-2699157-A2 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | The Regents of the University of California (US) | 2014-02-26 | — | — | EP | claimed |
| WO-2012145169-A2 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-26 | — | — | WO | claimed |
| EP-3345545-B1 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | UNIV CALIFORNIA (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3345545-B1 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | UNIV CALIFORNIA (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10751428-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-25 | — | — | US | disclosed |
| US-10751428-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-25 | — | — | US | disclosed |
| US-10232059-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-19 | — | — | US | disclosed |
| US-10232059-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3345545-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | The Regents of The University of California (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345545-A1 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | The Regents of The University of California (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2012145169-A2 | FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| EP-2454216-A1 | NON-POLAR AND POLAR LEAVING GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006610-A1 | NON-POLAR AND POLAR LEAVING GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| US-20090264732-A1 | IMAGING AGENTS AND METHODS OF USE THEREOF | HUNTINGTON MEDICAL RESEARCH INSTITUTES (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080171863-A1 | Method for Preparing of Organofluoro Compounds in Alcohol Solvents | FUTURECHEM CO., LTD. (KR) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238740-A1 | NON-POLAR AND POLAR LEAVING GROUPS | PGLS, RABGGTB, LNPEP | APP 1597/4885MAPT 3744/4885SNCA 2394/4885 |
| US-10751428-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | MAPT, PRNP, APP | APP 3/4885MAPT 1/4885SNCA 16/4885 |
| US-20080171863-A1 | Method for Preparing of Organofluoro Compounds in Alcohol Solvents | ADH5, ADH1C, ADH1A | APP 4775/4885MAPT 3439/4885SNCA 1993/4885 |
| US-20140140932-A1 | Functionalized Magnetic Nanoparticles and Use in Imaging Amyloid Deposits and Neurofibrillary Tangles | MAPT, PRNP, APP | APP 3/4885MAPT 1/4885SNCA 16/4885 |
| US-10232059-B2 | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles | MAPT, PRNP, APP | APP 3/4885MAPT 1/4885SNCA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.